Trandolapril PharmaS 0,5 mg tvrde kapsule Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

trandolapril pharmas 0,5 mg tvrde kapsule

pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - trandolapril - kapsula, tvrda - urbroj: 1 kapsula sadrži 0,50 mg trandolaprila

Trandolapril PharmaS 2 mg tvrde kapsule Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

trandolapril pharmas 2 mg tvrde kapsule

pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - trandolapril - kapsula, tvrda - urbroj: 1 kapsula sadrži 2 mg trandolaprila

Trandolapril PharmaS 4 mg tvrde kapsule Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

trandolapril pharmas 4 mg tvrde kapsule

pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - trandolapril - kapsula, tvrda - urbroj: 1 kapsula sadrži 4 mg trandolaprila

IBANDRONAT PHARMAS 150 mg/1 tableta filmom obložena tableta Bosnia na Hezegovina - Kroeshia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

ibandronat pharmas 150 mg/1 tableta filmom obložena tableta

pharmas d.o.o. sarajevo - ibandronska kiselina - filmom obložena tableta - 150 mg/1 tableta - 1 filmom obložena tableta sadrži: 150 mg ibandronska kiselina (u obliku natrijevog ibandronat hidrata)

Teriflunomid Pharmascience 14 mg filmom obložene tablete Korasia - Kroeshia - HALMED (Agencija za lijekove i medicinske proizvode)

teriflunomid pharmascience 14 mg filmom obložene tablete

pharmascience international limited, lampousas, 1, nicosia, cipar - teriflunomid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 14 mg teriflunomida

Olanzapine Glenmark Europe Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

olanzapine glenmark europe

glenmark arzneimittel gmbh - olanzapin - schizophrenia; bipolar disorder - psycholeptics - adultsolanzapine indiciran za liječenje shizofrenije. Оланзапин učinkovit u održavanju kliničkog poboljšanja u roku od nastavka terapije kod pacijenata koji su pokazali odgovor na liječenje . Оланзапин je indiciran za liječenje umjerene do teških maničnih epizoda. kod pacijenata epizoda kojega je manično reagirao na liječenje Оланзапин, Оланзапин je indiciran za prevenciju relapsa kod pacijenata s bipolarnim poremećajem.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Lamivudine Teva Pharma B.V. Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

lamivudine teva pharma b.v.

teva b.v.  - lamivudin - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - lamivudin teva pharma b. naznačena je kao dio antiretrovirusne kombinacijske terapije za liječenje odraslih i djece s infekcijom virusom humane imunodeficijencije (hiv).